These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31138411)

  • 1. Concentration-response studies of the chromosome-damaging effects of topoisomerase II inhibitors determined in vitro using human TK6 cells.
    Gollapudi P; Bhat VS; Eastmond DA
    Mutat Res Genet Toxicol Environ Mutagen; 2019 May; 841():49-56. PubMed ID: 31138411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catalytic inhibitors of topoisomerase II are DNA-damaging agents: induction of chromosomal damage by merbarone and ICRF-187.
    Wang L; Eastmond DA
    Environ Mol Mutagen; 2002; 39(4):348-56. PubMed ID: 12112387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytogenetic evidence that DNA topoisomerase II is not involved in radiation induced chromsome-type aberrations.
    Mosesso P; Pepe G; Ottavianelli A; Schinoppi A; Cinelli S
    Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():14-8. PubMed ID: 26520368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient induction of chromosome-type aberrations by topoisomerase II inhibitors closely associated with stabilization of the cleavable complex in cultured fibroblastic cells.
    Suzuki H; Ikeda T; Yamagishi T; Nakaike S; Nakane S; Ohsawa M
    Mutat Res; 1995 May; 328(2):151-61. PubMed ID: 7739599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential cell cycle-specificity for chromosomal damage induced by merbarone and etoposide in V79 cells.
    Wang L; Roy SK; Eastmond DA
    Mutat Res; 2007 Mar; 616(1-2):70-82. PubMed ID: 17174356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of the cytotoxic and genotoxic effects of ICRF-154 and bimolane, two catalytic inhibitors of topoisomerase II.
    Vuong MC; Hasegawa LS; Eastmond DA
    Mutat Res; 2013 Jan; 750(1-2):63-71. PubMed ID: 23000430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase II inhibitors fail to induce chromosome-type aberrations in etoposide-resistant cells: evidence for essential contribution of the cleavable complex formation to the induction of chromosome-type aberrations.
    Suzuki H; Tarumoto Y; Ohsawa M
    Mutagenesis; 1997 Jan; 12(1):29-33. PubMed ID: 9025094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
    Sehested M; Jensen PB
    Biochem Pharmacol; 1996 Apr; 51(7):879-86. PubMed ID: 8651936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the DNA topoisomerase II inhibitor merbarone in male mouse meiotic divisions in vivo: cell cycle arrest and induction of aneuploidy.
    Kallio M; Lähdetie J
    Environ Mol Mutagen; 1997; 29(1):16-27. PubMed ID: 9020303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosomal malsegregation and micronucleus induction in vitro by the DNA topoisomerase II inhibitor fisetin.
    Olaharski AJ; Mondrala ST; Eastmond DA
    Mutat Res; 2005 Apr; 582(1-2):79-86. PubMed ID: 15781213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragmentation of centromeric DNA and prevention of homologous chromosome separation in male mouse meiosis in vivo by the topoisomerase II inhibitor etoposide.
    Kallio M; Lähdetie J
    Mutagenesis; 1996 Sep; 11(5):435-43. PubMed ID: 8921504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tirapazamine: a hypoxia-activated topoisomerase II poison.
    Peters KB; Brown JM
    Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are topoisomerase II inhibitor-induced micronuclei in vitro a predictive marker for the compounds' ability to cause secondary leukemias after treatment?
    Stopper H; Boos G; Clark M; Gieseler F
    Toxicol Lett; 1999 Jan; 104(1-2):103-10. PubMed ID: 10048755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
    Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
    Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
    Hasinoff BB; Kuschak TI; Creighton AM; Fattman CL; Allan WP; Thampatty P; Yalowich JC
    Biochem Pharmacol; 1997 Jun; 53(12):1843-53. PubMed ID: 9256159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topoisomerase II inhibitors affect entry into mitosis and chromosome condensation in BHK cells.
    Anderson H; Roberge M
    Cell Growth Differ; 1996 Jan; 7(1):83-90. PubMed ID: 8788036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetic evaluation of the mechanism of cell death induced by the novel anthracenyl-amino acid topoisomerase II catalytic inhibitor NU/ICRF 500.
    Cummings J; Sumner AT; Slavotinek A; Meikle I; Macpherson JS; Smyth JF
    Mutat Res; 1995 Aug; 344(1-2):55-62. PubMed ID: 7565893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analyzing Mitotic Chromosome Structural Defects After Topoisomerase II Inhibition or Mutation.
    Giménez-Abián JF; Lane AB; Clarke DJ
    Methods Mol Biol; 2018; 1703():191-215. PubMed ID: 29177744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.